| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
|---|---|
| opioid | Originally, a term denoting synthetic narcotics resembling opiates but increasingly used to refer to both opiates and synthetic narcotics. (05 Mar 2000) |
| opioid agonist | <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression. (16 Dec 1997) |
| opioid partial agonist | <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response. (16 Dec 1997) |
| opioid peptides | The endogenous peptides with opiate-like activity. The three major classes currently recognised are the enkephalins, the dynorphins, and the endorphins. Each of these families derives from different precursors, proenkephalin, prodynorphin, and pro-opiomelanocortin, respectively. There are also at least three classes of opioid receptors, but the peptide families do not map to the receptors in a simple way. (12 Dec 1998) |
| opioid receptor | <pharmacology> A membrane protein, widely distributed in animal cells, but especially in the brain (enkephalin receptors) and gut. The natural ligands are the opiate peptide neurotransmitters, but the name is given because opiates are potent agonists that occupy the receptors and mimic the action of the natural transmitters. (18 Nov 1997) |
| opioid-related disorders | Disorders related or resulting from abuse or mis-use of opioids. (12 Dec 1998) |
| adrenergic alpha-antagonists | Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (12 Dec 1998) |
| adrenergic antagonists | Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine. (12 Dec 1998) |
| adrenergic beta-antagonists | Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (12 Dec 1998) |
| aldosterone antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of aldosterone. (12 Dec 1998) |
| androgen antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of androgens. (12 Dec 1998) |
| gaba antagonists | Drugs that bind to but do not activate gaba receptors, thereby blocking the actions of endogenous gaba or gaba agonists. (12 Dec 1998) |
| cholinergic antagonists | Drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. (12 Dec 1998) |
| muscarinic antagonists | Drugs that bind to but do not activate muscarinic cholinergic receptors (receptors, muscarinic), thereby blocking the actions of endogenous acetycholine or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antagonists that discriminate among the various muscarinic receptor subtypes and might allow better control of peripheral and central actions are under development. (12 Dec 1998) |